Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Market by Drugs (Antiandrogens, Anti-obesity, Antidepressant, Oral Contraceptives, and Insulin-sensitizing Agent), Surgery (Laparoscopic Ovarian Drilling and Ovarian Wedge Resection), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2158
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 178
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global polycystic ovarian syndrome treatment market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing demand for polycystic syndrome (PCOS) treatment drugs across world and rising cases of PCOS in the market.

Polycystic Ovarian Syndrome Treatment Market summary

Polycystic ovarian syndrome is a hormonal condition that affects women of childbearing age and is marked by the production of cysts on the ovaries. It is associated with hirsutism, obesity, diabetes, and infertility, hence it requires proper treatment. At present, there is no particular cure for PCOS; however, it can be treated with drugs such as anti-androgens, anti-obesity, antidepressant, oral contraceptives, and insulin-sensitizing agent.

The COVID-19 pandemic has had an impact on certain surgical procedures such as laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery published their findings that the patients undergoing surgery after contracting coronavirus were at increased risk of postoperative death and were recommended to avoid all non-emergent surgeries. The report further stated that patients who had contracted coronavirus and had surgery were on higher risk of mortality post-surgery and should avoid all non-emergent surgeries. However, in order to maintain normal surgical practices, regulatory authorities established a few guidelines unique to each profession that surgeons must implement and follow so as to continue to provide safe and effective care to their patients throughout the COVID-19 pandemic.

Market Trends, Drivers, Restraints, and Opportunities

  • Ongoing R&D activities and investment by key players in developing innovative and improved treatment devices with better safety and efficacy are expected to propel the market growth in the coming years.
  • Rising in genetic and hormonal diseases in growing population is a key factor propelling the market growth.
  • Delaying drugs approval by regulatory bodies such as the US Food and Drug Administration (FDA) in the US and other regulators among many countries present key factors hampering the growth of the market.
  • Various side effects of drugs in the treatment procedure is expected to hamper the market growth.
  • Several initiatives undertaken by government bodies in order to increase awareness about disorders among people are offering good opportunity to fuel the growth of the market in near future.

Scope of the Report

The report on the global polycystic ovarian syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Polycystic Ovarian Syndrome Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs (Antiandrogens, Anti-obesity, Antidepressant, Oral Contraceptives, and Insulin-sensitizing Agent) and Surgery (Laparoscopic Ovarian Drilling and Ovarian Wedge Resection)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Abbott; Bayer AG; Sanofi; Merck KGaA; Pfizer, Inc.; Bristol-Myer Squibb Co; Novartis AG.; and AstraZeneca

Market Segment Insights

Insulin- sensitizing agent segment is expected to register a key market share

Based on drugs, the global polycystic ovarian syndrome treatment market is segregated as antiandrogens, anti-obesity, antidepressant, oral contraceptives, and insulin-sensitizing agent. The insulin- sensitizing agent segment is expected to register a key market share during the forecast period. Various products containing Rosiglitazone, Troglitazone, and Pioglitazone are widely available in the market including Glucophage XR (Metformin) for the treatment of polycystic ovarian syndrome. Metabolic dysfunction in PCOS can lead to an increase in androgen secretion, which can influence insulin secretion and raise the risk of diabetes. Therefore, insulin-sensitizing drugs play an essential function in therapies as they lower insulin levels and reduce ovarian androgen production as well as balancing hormone levels.

Meanwhile, the oral contraceptive (OCPs) pills segment is also expected to upsurge in the market during the projected period due to the wide availability of oral contraceptive products such as Drospirenone, Ethinyl Estradiol, and Medroxyprogesterone Acetate. Severe menstrual pain, irregular menstrual cycle, acne, and premenstrual syndrome are common indicators of PCOS that are treated by using OCPs. Thus, the demand for OCPs segment is increasing, which further boost the segment growth.

Laparoscopic ovarian drilling segment is projected to expand substantially

On the basis of surgery, the market is bifurcated into laparoscopic ovarian drilling and ovarian wedge resection. The laparoscopic ovarian drilling segment is projected to expand substantially in the market in the coming years as it is commonly recommended by doctors in critical conditions. Due to the increasing cases of PCOS that causes infertility in women, the effect of medication decrease over time. Thus, surgery with the help of thin microscope through the belly is highly recommended and undertaken by specialist all over the world.  Furthermore, patients are recommended to this surgical technique since it is affordable and allows them to address their ailment quickly. Thus, it is expected to have a sizable market share during the forecast period.

North America is anticipated to constitute a key market share

In terms of regions, the global polycystic ovarian syndrome treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period. The growth of the market attributed to the increasing cases of overweight & obesity, further leads to increasing incidence of PCOS patient. In terms of procurement of advanced technology and early drugs released, the US and Canada have first move advantage in the market. Moreover, major players have strong base along with strong product portfolio in the region.

For example, an oral gonadotropin-releasing hormone antagonist, Elagolix (ABT-620) is being researched by AbbVie, a US-based business for the treatment of endometriosis and PCOS. The University of Illinois at Chicago funded clinical research has conducted the research in November 2019, to examine the effect of salsalate administration on insulin sensitivity and on the ovarian capacity to conceal androgen in PCOS.

Polycystic Ovarian Syndrome Treatment Market region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Polycystic Ovarian Syndrome Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Polycystic Ovarian Syndrome Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Polycystic Ovarian Syndrome Treatment Market - Supply Chain
  4.5. Global Polycystic Ovarian Syndrome Treatment Market Forecast
     4.5.1. Polycystic Ovarian Syndrome Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Polycystic Ovarian Syndrome Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Polycystic Ovarian Syndrome Treatment Market Absolute $ Opportunity
5. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
6. North America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
7. Latin America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
8. Europe Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Polycystic Ovarian Syndrome Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Polycystic Ovarian Syndrome Treatment Market: Market Share Analysis
  11.2. Polycystic Ovarian Syndrome Treatment Distributors and Customers
  11.3. Polycystic Ovarian Syndrome Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbott
     11.4.2. Bayer AG
     11.4.3. Sanofi
     11.4.4. Merck KGaA
     11.4.5. Pfizer, Inc.
     11.4.6. Bristol-Myer Squibb Co.
     11.4.7. Novartis AG
     11.4.8. AstraZeneca

Segments Covered in the Report
The global polycystic ovarian syndrome treatment market has been segmented on the basis of
Drugs

  • Antiandrogens
  • Anti-obesity
  • Antidepressant
  • Oral Contraceptives
  • Insulin-sensitizing Agent

Surgery

  • Laparoscopic Ovarian Drilling
  • Ovarian Wedge Resection

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Abbott
  • Bayer AG
  • Sanofi
  • Merck KGaA
  • Pfizer, Inc.
  • Bristol-Myer Squibb Co.
  • Novartis AG
  • AstraZeneca

 

 

Some of the major players competing in the market are Abbott; Bayer AG; Sanofi; Merck KGaA; Pfizer, Inc.; Bristol-Myer Squibb Co; Novartis AG.; and AstraZeneca. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional competition.

Bayer AG, and Evotec SE have launched a new five-year in January 2020, multi-target partnership with Celmatix Inc. for the development of numerous clinical candidates for the treatment of PCOS. Thus, it is projected to propel the market during the forecast period. Abbvie declared its ongoing clinical trial using the chemical Elagolix in January 2020, which was being examined for its safety and efficacy in women with polycystic ovarian syndrome. The business has conducted a Phase 2 multicenter, double-blind, randomized, and placebo-controlled research to evaluate Elagolix's efficiency of polycystic ovarian syndrome.

Polycystic Ovarian Syndrome Treatment Market keyplayers

Buy Report